文献速递呼吸危重症与机械通气

辛伐他汀早期干预对机械通气危重患者谵妄与昏迷的影响(MoDUS 试验)

Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Respir Med · 2017-07-19

MoDUS 是一项在英國 Watford 综合成人 ICU 开展的随机、双盲、安慰剂对照试验,纳入机械通气危重患者 142 例,1:1 分配至辛伐他汀 80 mg 每日或安慰剂,最长 28 天。主要结局为随机后 14 天内无谵妄且无昏迷的存活天数,两组差异无统计学意义,结果不支持辛伐他汀改变谵妄与昏迷病程的假设。

要点

  • 机械通气危重患者早期使用辛伐他汀 80 mg 未能延长 14 天内无谵妄且无昏迷的存活天数。

核心结论

  • 早期辛伐他汀治疗未能减少危重机械通气患者谵妄或昏迷的持续时间,结果不支持该假说。

研究设计与样本

  • 随机、双盲、安慰剂对照试验,在英國 Watford General Hospital 综合成人 ICU 开展。
  • 纳入 18 岁及以上、入 ICU 72 小时内需机械通气的危重患者,1:1 随机分配至辛伐他汀 80 mg 每日或安慰剂,最长 28 天。
  • 共 142 例纳入最终分析,辛伐他汀组 71 例、安慰剂组 71 例;采用意向性治疗分析。
  • 谵妄采用 ICU 意识模糊评估法(CAM-ICU)评估。

主要发现

  • 无患者发生与研究药物相关的严重不良事件。

临床怎么用

  • 对机械通气危重患者,不应以预防或缩短谵妄与昏迷为目的常规早期使用辛伐他汀。
  • 使用辛伐他汀期间需关注肌酸激酶升高,本试验中该不良事件在辛伐他汀组数值上更多但差异无统计学意义。

局限性

  • 原文摘要未报告样本量估算依据、单中心设计的具体局限及随访时长等局限信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Delirium in critically ill patients is associated with poor clinical outcomes. Neuroinflammation might be an important mechanism in the pathogenesis of delirium, and since simvastatin has anti-inflammatory properties it might reduce delirium. We aimed to establish whether early treatment with simvastatin would decrease the time that survivors of critical illness spent in delirium or coma. METHODS: We undertook this randomised, double-blind, placebo-controlled trial in a general adult intensive care unit (ICU) in Watford General Hospital (Watford, UK). We enrolled critically ill patients (≥18 years) needing mechanical ventilation within 72 h of admission. We randomly assigned patients (1:1 ratio) to receive either simvastatin 80 mg or placebo daily for up to a maximum of 28 days, irrespective of coma or delirium status. We assessed delirium using the Confusion Assessment Method for the ICU (CAM-ICU). The primary outcome was number of days alive and was assessed as delirium-free and coma-free in the first 14 days after being randomly allocated to receive treatment or placebo. ICU clinical and research staff and patients were masked to treatment. We did intention-to-treat analyses with no extrapolation. This trial is registered with the International Standard Randomised Controlled Trial Registry, number ISRCTN89079989. FINDINGS: Between Feb 1, 2013, and July 29, 2016, 142 patients were randomly assigned to receive simvastatin (n=71) or placebo (n=71), and were included in the final analysis. The mean number of days alive without delirium and without coma at day 14 did not differ significantly between the two groups (5·7 days [SD 5·1] with simvastatin and 6·1 days [5·2] with placebo; mean difference 0·4 days, 95% CI -1·3 to 2·1; p=0·66). The most common adverse event was an elevated creatine kinase concentration to more than ten times the upper limit of normal (eight [11%] in the simvastatin group vs three [4%] in the placebo group p=0·208). No patient had a serious adverse event related to the study drug. INTERPRETATION: These results do not support the hypothesis that simvastatin modifies duration of delirium and coma in critically ill patients. FUNDING: National Institute for Health Research.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Page VJ, Casarin A, Ely EW, et al. Evaluation of early administration of simvastatin in the prevention and treatment of delirium in critically ill patients undergoing mechanical ventilation (MoDUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2017. PMID: 28734823. doi:10.1016/S2213-2600(17)30234-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。